TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Studies on Safety and Efficacy of Zinc-ORS Compared to ORS Alone in Hospitalized Children With Severe and Complicated Acute Diarrhea
Brief Summary: Three-hundred-and-fifty-two males aged 1-36 months with acute non-dysenteric diarrhoea and no systemic illness will be enrolled in this clinical trial. Eligible children will be stratified by their age (1up to 5 months, 6-35 months). Within the two age strata the patients will be randomized to receive zinc-ORS (fortified with 40 mg elemental zinc as zinc gluconate per litre) or standard WHO ORS. The major outcome measures will be stool output and duration of diarrhea. The safety of administering zinc will be determined by examining the effect of zinc ingestion on vomiting, sodium and potassium homeostasis, plasma zinc and copper, and iron stores and concentration of serum transferrin receptor.


Options:
A: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
B: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A
C: Arm Label: Zinc gluconate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc; Assigned to Arm(s): Placebo, Zinc gluconate
D: Intervention Type: DRUG; Name: Zinc sulphate; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Brief Summary: The purpose of this study is to determine whether pregabalin is an effective treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome.


Options:
A: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
B: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Silodosin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 4 mg | Arm Label: Silodosin 8 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 8 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Silodosin 8 mg; Assigned to Arm(s): Silodosin 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Silodosin 4 mg; Assigned to Arm(s): Silodosin 4 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia
Brief Summary: We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks


Options:
A: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: galantamine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia
Brief Summary: We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
B: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Buprenorphine plaster; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine plaster | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Buprenorphine plaster; Assigned to Arm(s): Buprenorphine plaster | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin
C: Arm Label: Citalopram and psychosocial intervention; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Arm Label: Placebo and psychosocial intervention; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): Citalopram and psychosocial intervention | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo and psychosocial intervention
D: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia
Brief Summary: We plan to evaluate the use of memantine in Alzheimer's disease to control agitation in the acute situation i.e under 12 weeks


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
D: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Double-Blind Placebo Controlled Study on Influenza Vaccination in Prevention From Coronary Events in Patients With Coronary Artery Disease Confirmed by Angiography
Brief Summary: Background: Influenza vaccination is recommended in patients (pts) with cardiovascular disease, however there is a shortage of clinical studies proving its protective effect on clinical course of coronary artery disease (CAD). The aim of the study was to evaluate the effect of influenza vaccination on the incidence of coronary events in pts with CAD confirmed by coronary angiography.


Options:
A: Arm Label: FluNG Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Bio's influenza vaccine GSK2186877A | Arm Label: Fluarix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fluarix TM | Intervention Type: BIOLOGICAL; Name: GSK Bio's influenza vaccine GSK2186877A; Assigned to Arm(s): FluNG Group | Intervention Type: BIOLOGICAL; Name: Fluarix TM; Assigned to Arm(s): Fluarix Group
B: Intervention Type: DRUG; Name: Influenza vaccination; Assigned to Arm(s): N/A
C: Arm Label: active vaccine; Type: EXPERIMENTAL; Interventions: Biological: Influenza vaccination: Influvac (SolvayPharma) | Arm Label: placebo vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo influenza vaccine | Intervention Type: BIOLOGICAL; Name: Influenza vaccination: Influvac (SolvayPharma); Assigned to Arm(s): active vaccine | Intervention Type: BIOLOGICAL; Name: placebo influenza vaccine; Assigned to Arm(s): placebo vaccine
D: Arm Label: MI plus respiratory illness; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Masked Study to Compare The Safety and Efficacy of Bilateral 0.5%, 0.1% & 0.01% Atropine Treatment In Controlling Progression of Myopia In Children
Brief Summary: The purpose of this study is to find an optimal dose of atropine for preventing the rapid progression of myopia in children by comparing the efficacy, safety and functional impact of binocular treatment with 0.5%, 0.1% and 0.01% atropine and to develop a treatment regimen for the routine management of childhood myopia.


Options:
A: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
B: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals
C: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
D: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Masked Study to Compare The Safety and Efficacy of Bilateral 0.5%, 0.1% & 0.01% Atropine Treatment In Controlling Progression of Myopia In Children
Brief Summary: The purpose of this study is to find an optimal dose of atropine for preventing the rapid progression of myopia in children by comparing the efficacy, safety and functional impact of binocular treatment with 0.5%, 0.1% and 0.01% atropine and to develop a treatment regimen for the routine management of childhood myopia.


Options:
A: Intervention Type: DEVICE; Name: Polymethyl Methacrylate-Silicone Contact Lenses; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Polymethyl Methacrylate Contact Lenses; Assigned to Arm(s): N/A
B: Arm Label: Bifocal Contact Lenses; Type: EXPERIMENTAL; Interventions: Device: Bifocal Contact Lenses | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo Control | Intervention Type: DEVICE; Name: Bifocal Contact Lenses; Assigned to Arm(s): Bifocal Contact Lenses | Intervention Type: DEVICE; Name: Placebo Control; Assigned to Arm(s): Control
C: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: increasing time spent outdoors | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: increasing time spent outdoors; Assigned to Arm(s): intervention group
D: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD
Brief Summary: The primary aim of this project is to examine whether administration of D-Cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) receptor agonist that has been shown to facilitate fear extinction, enhances the therapeutic benefit of exposure-based cognitive behavioral therapy (CBT) in OEF/OIF veterans with PTSD.


Options:
A: Arm Label: D-cycloserine plus exposure therapy; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine, Behavioral: Exposure therapy | Arm Label: Placebo plus exposure therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Exposure therapy, Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus exposure therapy | Intervention Type: BEHAVIORAL; Name: Exposure therapy; Assigned to Arm(s): D-cycloserine plus exposure therapy, Placebo plus exposure therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus exposure therapy
B: Arm Label: D-Cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Exposure therapy, Drug: D-Cycloserine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Exposure therapy, Other: Placebo pill | Intervention Type: BEHAVIORAL; Name: Exposure therapy; Assigned to Arm(s): D-Cycloserine, Placebo | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): D-Cycloserine | Intervention Type: OTHER; Name: Placebo pill; Assigned to Arm(s): Placebo
C: Arm Label: Cognitive-behavioral therapy + placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: Placebo pill | Arm Label: Cognitive-behavioral therapy + D-cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: D-cycloserine | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive-behavioral therapy + D-cycloserine, Cognitive-behavioral therapy + placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): Cognitive-behavioral therapy + D-cycloserine | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Cognitive-behavioral therapy + placebo
D: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: Placebo | Arm Label: D-Cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: D-Cycloserine | Intervention Type: BEHAVIORAL; Name: Individual Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): D-Cycloserine, Sugar Pill | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis
Brief Summary: The purpose of this study is comparing the efficacy of tacrolimus and mycophenolate mofetil for the initial therapy of active lupus glomerulonephritis.


Options:
A: Arm Label: Tacrolimus+Mycophenolate mofetil; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus+Mycophenolate mofetil | Arm Label: Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Tacrolimus+Mycophenolate mofetil; Assigned to Arm(s): Tacrolimus+Mycophenolate mofetil | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide
B: Arm Label: Induction Phase: Mycophenolate mofetil; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil (MMF), Drug: Corticosteroid | Arm Label: Induction Phase: Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Corticosteroid | Arm Label: Maintenance Phase: Mycophenolate mofetil; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil (MMF), Drug: Placebo to Azathioprine, Drug: Corticosteroid | Arm Label: Maintenance Phase: Azathioprine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Drug: Placebo to Mycophenolate mofetil, Drug: Corticosteroid | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Induction Phase: Mycophenolate mofetil, Maintenance Phase: Mycophenolate mofetil | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Induction Phase: Cyclophosphamide | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Maintenance Phase: Azathioprine | Intervention Type: DRUG; Name: Placebo to Azathioprine; Assigned to Arm(s): Maintenance Phase: Mycophenolate mofetil | Intervention Type: DRUG; Name: Placebo to Mycophenolate mofetil; Assigned to Arm(s): Maintenance Phase: Azathioprine | Intervention Type: DRUG; Name: Corticosteroid; Assigned to Arm(s): Induction Phase: Cyclophosphamide, Induction Phase: Mycophenolate mofetil, Maintenance Phase: Azathioprine, Maintenance Phase: Mycophenolate mofetil
C: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus | Arm Label: mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil
D: Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial
Brief Summary: The purposes of this study are to determine whether intra-arterial injection of autologous stem cells is effective in the treatment of chronic limb ischemia (CLI), to characterize stem cell dysfunction in patients with CLI, and to relate the stem cell function with clinical outcome.


Options:
A: Intervention Type: DEVICE; Name: Bone marrow concentration device; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
C: Arm Label: Autologous Bone Marrow Mononuclear Cells; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells; Assigned to Arm(s): Autologous Bone Marrow Mononuclear Cells
D: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: Bone marrow punction, Procedure: BM-MNC infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Bone marrow punction, Procedure: Placebo infusion | Intervention Type: PROCEDURE; Name: Bone marrow punction; Assigned to Arm(s): BM-MNC, Placebo | Intervention Type: PROCEDURE; Name: BM-MNC infusion; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: Placebo infusion; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial
Brief Summary: The purposes of this study are to determine whether intra-arterial injection of autologous stem cells is effective in the treatment of chronic limb ischemia (CLI), to characterize stem cell dysfunction in patients with CLI, and to relate the stem cell function with clinical outcome.


Options:
A: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: Bone marrow punction, Procedure: BM-MNC infusion | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Bone marrow punction, Procedure: Placebo infusion | Intervention Type: PROCEDURE; Name: Bone marrow punction; Assigned to Arm(s): BM-MNC, Placebo | Intervention Type: PROCEDURE; Name: BM-MNC infusion; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: Placebo infusion; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Intervention Type: PROCEDURE; Name: intraarterial stem cell therapy; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Stem cells; Assigned to Arm(s): 1, 2
C: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC

Answer: A